valproic acid has been researched along with Leukemia, Myeloid, Acute in 68 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients." | 9.12 | Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. ( Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H, 2006) |
| "Acute myelogenous leukemia (AML) patients (24 consecutive patients, median age 71 years, 17 high-risk disease) were treated with all-trans retinoic acid, theophylline and valproic acid." | 7.75 | A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. ( Bruserud, O; Corbascio, M; Gjertsen, BT; Lassalle, P; Ryningen, A; Stapnes, C, 2009) |
| "We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients." | 5.12 | Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. ( Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H, 2006) |
| " Multiplexing mAbs against CD11b and CD11c provided surrogate imaging biomarkers of differentiation therapy in an acute promyelocytic leukemia model treated with all-trans retinoic acid combined with the histone-deacetylase inhibitor valproic acid." | 3.79 | Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. ( Bruserud, Ø; Gjertsen, BT; McCormack, E; Mujić, M; Osdal, T, 2013) |
| "Acute myelogenous leukemia (AML) patients (24 consecutive patients, median age 71 years, 17 high-risk disease) were treated with all-trans retinoic acid, theophylline and valproic acid." | 3.75 | A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. ( Bruserud, O; Corbascio, M; Gjertsen, BT; Lassalle, P; Ryningen, A; Stapnes, C, 2009) |
| " We conclude that VPA is a safe and effective treatment option for MDS and AML patients, particularly when used in conjunction with all-trans retinoic acid, DNA-hypomethylating drugs, and hydralazine." | 3.01 | Efficacy and Safety of Valproic Acid in Myelodysplastic Syndrome and Acute Myeloid Leukemia; a Narrative Review. ( Mahdiani, S; Mohammadpour, AH; Omidkhoda, N; Rahimi, H; Samadi, S, 2023) |
| "DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias." | 2.94 | Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. ( Becker, H; Brugger, W; Bug, G; Crysandt, M; De Wit, M; Döhner, H; Döhner, K; Duyster, J; Ganser, A; Germing, U; Giagounidis, A; Götze, KS; Grishina, O; Hackanson, B; Heil, G; Heuser, M; Jost, E; Krauter, J; Kuendgen, A; Lindemann, HW; Lübbert, M; May, AM; Müller-Tidow, C; Neubauer, A; Salih, HR; Schittenhelm, MM; Schlenk, RF; Schmoor, C; Scholl, S; Schwaenen, C; Thol, F; Wäsch, R, 2020) |
| " Patients are randomized to one of the four treatment groups: DAC alone or in combination with VPA or ATRA or with both add-on drugs." | 2.80 | DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute mye ( Cieslik, C; Döhner, K; Grishina, O; Hackanson, B; Lübbert, M; Lubrich, B; May, AM; Müller, MJ; Schmoor, C, 2015) |
| "The outcome of patients with acute myeloid leukemia who are older than 60 years has remained poor because of unfavorable disease characteristics and patient-related factors." | 2.79 | Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. ( Brossart, P; Brugger, W; Derigs, HG; Döhner, H; Döhner, K; Gaidzik, VI; Göttlicher, M; Götze, K; Greil, R; Heil, G; Held, G; Horst, HA; Kirchen, H; Köhne, CH; Koller, E; Kremers, S; Matzdorff, A; Nachbaur, D; Paschka, P; Raghavachar, A; Ringhoffer, M; Schlenk, RF; Tassara, M; Wattad, M; Wulf, G, 2014) |
| " The authors examined the in vitro and clinical activity of the histone deacetylase inhibitor valproic acid (VA) combined with cytosine arabinoside (AraC) in elderly patients with AML unsuited to intensive therapy." | 2.77 | Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. ( Fan, HM; Gill, D; Keane, C; Lane, S; McMillan, NA; Mollee, P; Murphy, R; Saunders, N; Spurr, T, 2012) |
| "Thirty-one elderly AML/RAEB patients (AML n=25; RAEB n=6) with a high rate of comorbidity were entered in a phase II study with low-dose cytarabine (Ara-C) and VPA." | 2.76 | Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. ( Alvaro, MG; Baraldi, A; Ciravegna, G; Corsetti, MT; De Paoli, L; Gatto, S; Levis, A; Perticone, S; Pietrasanta, D; Pini, M; Primon, V; Salvi, F; Tonso, A; Zallio, F, 2011) |
| " In conclusion, the combination studied is safe and has significant clinical activity." | 2.73 | Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. ( Cortes, J; Estey, EH; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Issa, JP; Kantarjian, HM; Ouzounian, S; Pierce, S; Quezada, A; Ravandi, F; Soriano, AO; Wierda, WG; Yang, H, 2007) |
| "To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)." | 2.73 | Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. ( Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T, 2007) |
| "Valproic acid (VPA) is an HDACi and has been known as anti-epileptic agent for many years." | 2.44 | Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. ( Bellos, F; Mahlknecht, U, 2008) |
| "Valproic acid (VPA) is an anti-epileptic drug that also acts as a class I histone deacetylase inhibitor." | 1.40 | Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity. ( Heo, SK; Jo, JC; Kim, H; Noh, EK; Park, JH; Yoon, DJ, 2014) |
| "Although TP53 mutations are rare in acute myeloid leukemia (AML), wild type p53 function is habitually annulled through overexpression of MDM2 or through various mechanisms including epigenetic silencing by histone deacetylases (HDACs)." | 1.38 | Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. ( Bruserud, O; Forthun, RB; Gausdal, G; Gjertsen, BT; Haaland, I; Huseby, S; Knappskog, S; Lorens, JB; McCormack, E; Micklem, DR; Venås, G, 2012) |
| "Valproic acid (VPA) has extensive effects on leukemic blasts through its inhibition of histone deacetylases." | 1.38 | Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically. ( Mejstrikova, E; Smetana, K; Starkova, J; Stary, J; Trka, J; Zapotocky, M, 2012) |
| "Co-treatment with VPA and bortezomib on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cell lines resulted in marked inhibition of proliferation and induction of apoptosis, including a striking increase in mitochondrial injury, caspase cascade activation, and altered expression of Bcl-2 family proteins." | 1.37 | Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. ( Chen, L; Li, JM; Shen, ZX; Wang, AH; Wei, L; Wu, WL; Zhao, SQ, 2011) |
| "We report that acute myeloid leukemia (AML) with an aberrant histone methyltransferase, the mixed lineage leukemia partial tandem duplication (MLL-PTD), exhibits increased global DNA methylation versus AML with MLL-wildtype (MLL-WT; P = ." | 1.35 | DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. ( Bloomfield, CD; Caligiuri, MA; Davuluri, R; Hackanson, B; Liu, C; Liu, S; Liyanarachchi, S; Maharry, K; Marcucci, G; Margeson, D; Plass, C; Rush, LJ; Wen, J; Whitman, SP; Witte, T; Yu, L, 2008) |
| "In t(8;21) acute myeloid leukemia (AML), the AML1/ETO fusion protein promotes leukemogenesis by recruiting class I histone deacetylase (HDAC)-containing repressor complex to the promoter of AML1 target genes." | 1.34 | Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. ( Blum, W; Chan, KK; Huynh, L; Klisovic, RB; Liu, S; Liu, Z; Marcucci, G; Neviani, P; Pang, J; Paschka, P; Perrotti, D; Vukosavljevic, T; Yu, J, 2007) |
| "Valproic acid (VPA) has been demonstrated to be able to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid (ATRA) in inducing the differentiation of acute myeloid leukemia (AML) cells." | 1.33 | Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. ( Chaibi, P; Degos, L; Dombret, H; Raffoux, E, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.47) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (32.35) | 29.6817 |
| 2010's | 38 (55.88) | 24.3611 |
| 2020's | 7 (10.29) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Y | 1 |
| Southam, AD | 1 |
| Trova, S | 1 |
| Beke, F | 1 |
| Alhazmi, B | 1 |
| Francis, T | 1 |
| Radotra, A | 1 |
| di Maio, A | 1 |
| Drayson, MT | 1 |
| Bunce, CM | 2 |
| Khanim, FL | 2 |
| Adès, L | 2 |
| Duployez, N | 1 |
| Guerci-Bresler, A | 2 |
| Laribi, K | 1 |
| Peterlin, P | 1 |
| Vey, N | 2 |
| Thepot, S | 2 |
| Wickenhauser, S | 1 |
| Zerazhi, H | 1 |
| Stamatoullas, A | 2 |
| Wattel, E | 2 |
| Recher, C | 2 |
| Toma, A | 2 |
| Dimicoli-Salazar, S | 1 |
| Braun, T | 1 |
| Beyne-Rauzy, O | 2 |
| Marolleau, JP | 2 |
| Cheze, S | 2 |
| Park, S | 2 |
| Cluzeau, T | 1 |
| Nimubona, S | 1 |
| Bordessoule, D | 2 |
| Benramdane, R | 1 |
| Quesnel, B | 1 |
| Amé, S | 1 |
| de Botton, S | 2 |
| Chermat, F | 1 |
| Preudhomme, C | 1 |
| Chevret, S | 2 |
| Fenaux, P | 4 |
| Zhang, H | 1 |
| Song, W | 1 |
| Ma, X | 1 |
| Yu, M | 1 |
| Chen, L | 2 |
| Tao, Y | 1 |
| Omidkhoda, N | 1 |
| Mahdiani, S | 1 |
| Samadi, S | 1 |
| Rahimi, H | 1 |
| Mohammadpour, AH | 1 |
| Wen, J | 2 |
| Chen, Y | 1 |
| Yang, J | 1 |
| Dai, C | 1 |
| Yu, S | 1 |
| Zhong, W | 1 |
| Liu, L | 2 |
| He, C | 1 |
| Zhang, W | 1 |
| Yang, T | 1 |
| Hu, J | 1 |
| Grønningsæter, IS | 1 |
| Fredly, HK | 1 |
| Gjertsen, BT | 13 |
| Hatfield, KJ | 1 |
| Bruserud, Ø | 9 |
| Lübbert, M | 4 |
| Grishina, O | 2 |
| Schmoor, C | 2 |
| Schlenk, RF | 3 |
| Jost, E | 1 |
| Crysandt, M | 1 |
| Heuser, M | 1 |
| Thol, F | 1 |
| Salih, HR | 1 |
| Schittenhelm, MM | 1 |
| Germing, U | 2 |
| Kuendgen, A | 3 |
| Götze, KS | 1 |
| Lindemann, HW | 1 |
| Müller-Tidow, C | 1 |
| Heil, G | 2 |
| Scholl, S | 1 |
| Bug, G | 3 |
| Schwaenen, C | 1 |
| Giagounidis, A | 1 |
| Neubauer, A | 2 |
| Krauter, J | 1 |
| Brugger, W | 2 |
| De Wit, M | 1 |
| Wäsch, R | 1 |
| Becker, H | 1 |
| May, AM | 2 |
| Duyster, J | 1 |
| Döhner, K | 4 |
| Ganser, A | 1 |
| Hackanson, B | 4 |
| Döhner, H | 3 |
| Haaland, I | 2 |
| Hjelle, SM | 1 |
| Reikvam, H | 3 |
| Sulen, A | 2 |
| Ryningen, A | 5 |
| McCormack, E | 6 |
| Hamel, JF | 1 |
| Kelaidi, C | 1 |
| Campelo, MD | 1 |
| Santini, V | 2 |
| Sekeres, MA | 2 |
| Balleari, E | 1 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 2 |
| Müller-Thomas, C | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Cony-Makhoul, P | 1 |
| Rose, C | 1 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Hovland, R | 1 |
| Forthun, RB | 4 |
| Erdal, S | 1 |
| Fredly, H | 2 |
| Blagitko-Dorfs, N | 1 |
| Schlosser, P | 1 |
| Greve, G | 1 |
| Pfeifer, D | 1 |
| Meier, R | 1 |
| Baude, A | 1 |
| Brocks, D | 1 |
| Plass, C | 3 |
| Hellesøy, M | 1 |
| Kopperud, RK | 1 |
| Sjøholt, G | 1 |
| Wang, LH | 2 |
| Zhang, ZH | 2 |
| Zhao, L | 2 |
| Zhu, CM | 2 |
| Zhao, LS | 1 |
| Hao, CL | 2 |
| Torgersen, ML | 1 |
| Engedal, N | 1 |
| Bøe, SO | 1 |
| Hokland, P | 1 |
| Simonsen, A | 1 |
| Liu, P | 1 |
| Tian, X | 1 |
| Tassara, M | 1 |
| Brossart, P | 1 |
| Held, G | 1 |
| Horst, HA | 1 |
| Ringhoffer, M | 1 |
| Köhne, CH | 1 |
| Kremers, S | 1 |
| Raghavachar, A | 1 |
| Wulf, G | 1 |
| Kirchen, H | 1 |
| Nachbaur, D | 1 |
| Derigs, HG | 1 |
| Wattad, M | 1 |
| Koller, E | 1 |
| Matzdorff, A | 1 |
| Greil, R | 1 |
| Paschka, P | 2 |
| Gaidzik, VI | 1 |
| Göttlicher, M | 1 |
| Heo, SK | 1 |
| Noh, EK | 1 |
| Yoon, DJ | 1 |
| Jo, JC | 1 |
| Park, JH | 1 |
| Kim, H | 1 |
| Issa, JP | 3 |
| Garcia-Manero, G | 5 |
| Huang, X | 1 |
| Cortes, J | 3 |
| Ravandi, F | 3 |
| Jabbour, E | 2 |
| Borthakur, G | 1 |
| Brandt, M | 1 |
| Pierce, S | 2 |
| Kantarjian, HM | 4 |
| Ornstein, MC | 1 |
| Mukherjee, S | 1 |
| Lubrich, B | 1 |
| Cieslik, C | 1 |
| Müller, MJ | 1 |
| Leitch, C | 1 |
| Osdal, T | 2 |
| Andresen, V | 1 |
| Molland, M | 1 |
| Kristiansen, S | 1 |
| Nguyen, XN | 1 |
| Zhu, X | 1 |
| Liu, X | 1 |
| Cheng, Z | 1 |
| Zhu, J | 1 |
| Xu, L | 1 |
| Wang, F | 1 |
| Qi, W | 1 |
| Yan, J | 1 |
| Liu, N | 2 |
| Sun, Z | 1 |
| Liu, H | 1 |
| Peng, X | 1 |
| Hao, Y | 1 |
| Zheng, N | 1 |
| Wu, Q | 1 |
| Davood, ZA | 1 |
| Shamsi, S | 1 |
| Ghaedi, H | 1 |
| Sahand, RI | 1 |
| Mojtaba, G | 1 |
| Mahdi, T | 1 |
| Reza, M | 1 |
| Ebrahimi, MJ | 1 |
| Miri-Moosavi, RS | 1 |
| Boosaliki, S | 1 |
| Davood, OM | 1 |
| Wang, C | 1 |
| Wang, L | 1 |
| Gao, L | 1 |
| Cheng, H | 1 |
| Tang, G | 1 |
| Hu, X | 1 |
| Wang, J | 1 |
| Rücker, FG | 1 |
| Lang, KM | 1 |
| Fütterer, M | 1 |
| Komarica, V | 1 |
| Schmid, M | 1 |
| Knudsen, S | 1 |
| Bullinger, L | 1 |
| Romanski, A | 2 |
| Whitman, SP | 1 |
| Liyanarachchi, S | 1 |
| Liu, S | 3 |
| Rush, LJ | 1 |
| Maharry, K | 1 |
| Margeson, D | 1 |
| Davuluri, R | 1 |
| Witte, T | 1 |
| Yu, L | 1 |
| Liu, C | 1 |
| Bloomfield, CD | 1 |
| Marcucci, G | 3 |
| Caligiuri, MA | 1 |
| Fabre, C | 1 |
| Grosjean, J | 1 |
| Tailler, M | 1 |
| Boehrer, S | 1 |
| Perfettini, JL | 1 |
| Kroemer, G | 1 |
| Stapnes, C | 4 |
| Lassalle, P | 1 |
| Corbascio, M | 2 |
| Bruserud, O | 3 |
| Bradbury, CA | 1 |
| Arrazi, J | 1 |
| Hayden, RE | 1 |
| Rye, A | 1 |
| Basu, S | 1 |
| MacWhannell, A | 1 |
| Sawers, A | 1 |
| Griffiths, M | 1 |
| Cook, M | 1 |
| Freeman, S | 1 |
| Nightingale, KP | 1 |
| Grimwade, D | 1 |
| Falciani, F | 1 |
| Turner, BM | 1 |
| Craddock, C | 1 |
| Bellos, F | 1 |
| Mahlknecht, U | 1 |
| Poggi, A | 1 |
| Catellani, S | 1 |
| Garuti, A | 1 |
| Pierri, I | 1 |
| Gobbi, M | 1 |
| Zocchi, MR | 1 |
| Gul, H | 1 |
| Marquez-Curtis, LA | 1 |
| Jahroudi, N | 1 |
| Larratt, LM | 1 |
| Janowska-Wieczorek, A | 1 |
| Radaelli, E | 1 |
| Marchesi, F | 1 |
| Patton, V | 1 |
| Scanziani, E | 1 |
| Xie, C | 2 |
| Edwards, H | 2 |
| Xu, X | 1 |
| Zhou, H | 1 |
| Buck, SA | 2 |
| Stout, ML | 1 |
| Yu, Q | 1 |
| Rubnitz, JE | 1 |
| Matherly, LH | 2 |
| Taub, JW | 2 |
| Ge, Y | 2 |
| Smetana, K | 2 |
| Zápotocký, M | 2 |
| Robak, T | 1 |
| Szmigielska-Kapłon, A | 1 |
| Pluta, A | 1 |
| Grzybowska-Izydorczyk, O | 1 |
| Wolska, A | 1 |
| Czemerska, M | 1 |
| Wierzbowska, A | 1 |
| Yang, H | 3 |
| Fang, Z | 1 |
| Wei, Y | 1 |
| Hu, Y | 1 |
| Calin, GA | 1 |
| Raffoux, E | 2 |
| Cras, A | 1 |
| Boëlle, PY | 1 |
| de Labarthe, A | 1 |
| Turlure, P | 1 |
| Reman, O | 1 |
| Gardin, C | 1 |
| Victor, M | 1 |
| Maury, S | 1 |
| Rousselot, P | 1 |
| Malfuson, JV | 1 |
| Maarek, O | 1 |
| Daniel, MT | 1 |
| Degos, L | 2 |
| Chomienne, C | 1 |
| Dombret, H | 2 |
| Wang, AH | 1 |
| Wei, L | 1 |
| Zhao, SQ | 1 |
| Wu, WL | 1 |
| Shen, ZX | 1 |
| Li, JM | 1 |
| Corsetti, MT | 1 |
| Salvi, F | 1 |
| Perticone, S | 1 |
| Baraldi, A | 1 |
| De Paoli, L | 1 |
| Gatto, S | 1 |
| Pietrasanta, D | 1 |
| Pini, M | 1 |
| Primon, V | 1 |
| Zallio, F | 1 |
| Tonso, A | 1 |
| Alvaro, MG | 1 |
| Ciravegna, G | 1 |
| Levis, A | 1 |
| Venås, G | 1 |
| Huseby, S | 1 |
| Gausdal, G | 1 |
| Knappskog, S | 1 |
| Micklem, DR | 1 |
| Lorens, JB | 1 |
| Lane, S | 1 |
| Gill, D | 1 |
| McMillan, NA | 1 |
| Saunders, N | 1 |
| Murphy, R | 1 |
| Spurr, T | 1 |
| Keane, C | 1 |
| Fan, HM | 1 |
| Mollee, P | 1 |
| Mejstrikova, E | 1 |
| Stary, J | 1 |
| Trka, J | 1 |
| Starkova, J | 1 |
| Lograsso, SB | 1 |
| Sampath, D | 1 |
| Sengupta, T | 1 |
| Skjeldam, HK | 1 |
| Lindvall, JM | 1 |
| Nilsen, H | 1 |
| Mujić, M | 1 |
| Barbetti, V | 1 |
| Gozzini, A | 1 |
| Cheloni, G | 1 |
| Marzi, I | 1 |
| Fabiani, E | 1 |
| Dello Sbarba, P | 1 |
| Rovida, E | 1 |
| Trus, MR | 1 |
| Yang, L | 1 |
| Suarez Saiz, F | 1 |
| Bordeleau, L | 1 |
| Jurisica, I | 1 |
| Minden, MD | 1 |
| Siitonen, T | 1 |
| Koistinen, P | 1 |
| Savolainen, ER | 1 |
| Chaibi, P | 1 |
| Ritter, M | 1 |
| Wassmann, B | 1 |
| Schoch, C | 1 |
| Heinzel, T | 1 |
| Schwarz, K | 1 |
| Kramer, OH | 1 |
| Kampfmann, M | 1 |
| Hoelzer, D | 1 |
| Ruthardt, M | 1 |
| Ottmann, OG | 1 |
| Anensen, N | 1 |
| Skavland, J | 1 |
| Børresen-Dale, AL | 1 |
| Qi, H | 1 |
| Ratnam, M | 1 |
| Sanchez-Gonzalez, B | 1 |
| Rosner, G | 1 |
| Verstovsek, S | 1 |
| Rytting, M | 1 |
| Wierda, WG | 2 |
| Koller, C | 1 |
| Xiao, L | 1 |
| Faderl, S | 2 |
| Estrov, Z | 2 |
| O'brien, S | 1 |
| Estey, E | 1 |
| Bueso-Ramos, C | 1 |
| Fiorentino, J | 1 |
| Cimino, G | 1 |
| Lo-Coco, F | 1 |
| Fenu, S | 1 |
| Travaglini, L | 1 |
| Finolezzi, E | 1 |
| Mancini, M | 1 |
| Nanni, M | 1 |
| Careddu, A | 1 |
| Fazi, F | 1 |
| Padula, F | 1 |
| Fiorini, R | 1 |
| Spiriti, MA | 1 |
| Petti, MC | 1 |
| Venditti, A | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Pelicci, PG | 1 |
| Nervi, C | 1 |
| ten Cate, B | 1 |
| Samplonius, DF | 1 |
| Bijma, T | 1 |
| de Leij, LF | 1 |
| Helfrich, W | 1 |
| Bremer, E | 1 |
| Klisovic, RB | 2 |
| Vukosavljevic, T | 2 |
| Yu, J | 1 |
| Huynh, L | 2 |
| Pang, J | 1 |
| Neviani, P | 1 |
| Liu, Z | 2 |
| Blum, W | 2 |
| Chan, KK | 2 |
| Perrotti, D | 1 |
| Soriano, AO | 1 |
| Giles, F | 1 |
| Ouzounian, S | 1 |
| Quezada, A | 1 |
| Estey, EH | 1 |
| Devine, H | 1 |
| Lozanski, G | 1 |
| Kefauver, C | 1 |
| Devine, SM | 1 |
| Heerema, NA | 1 |
| Murgo, A | 1 |
| Grever, MR | 1 |
| Byrd, JC | 1 |
| Hatfield, K | 1 |
| Øyan, AM | 1 |
| Eide, GE | 1 |
| Kalland, KH | 1 |
| Diermayr, S | 1 |
| Himmelreich, H | 1 |
| Durovic, B | 1 |
| Mathys-Schneeberger, A | 1 |
| Siegler, U | 1 |
| Langenkamp, U | 1 |
| Hofsteenge, J | 1 |
| Gratwohl, A | 1 |
| Tichelli, A | 1 |
| Paluszewska, M | 1 |
| Wiktor-Jedrzejczak, W | 1 |
| Kalberer, CP | 1 |
| Wodnar-Filipowicz, A | 1 |
| Fischkoff, SA | 1 |
| Walter, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leu[NCT00867672] | Phase 2 | 204 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Azacitidine in Combination With or Without All-trans Retinoic Acid in Newly Diagnosed Unfit Acute Myeloid Leukemia or Intermediate,High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria[NCT05175508] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Differentiation Induction Therapy for Acute Myelogenous Leukemia[NCT00175812] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Treatment of Acute Myelogenous Leukemia With the Histone Deacetylase Inhibitor Valproic Cid in Combination With All-trans Retinoic Acid (ATRA) and Low Dose Cytarabine[NCT00995332] | Phase 1/Phase 2 | 36 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| Phase III - Study on All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia[NCT00151255] | Phase 3 | 500 participants (Anticipated) | Interventional | 2004-06-30 | Completed | ||
| Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736] | Early Phase 1 | 42 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial[NCT04482621] | Phase 2 | 33 participants (Actual) | Interventional | 2020-09-14 | Active, not recruiting | ||
| Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy[NCT01617226] | Phase 2 | 260 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Phase I/II Study of 5-aza-2'-Deoxycytidine and Valproic Acid in Patients With Relapsed/Refractory Leukemia or Myelodysplastic Syndromes[NCT00075010] | Phase 1/Phase 2 | 54 participants (Actual) | Interventional | 2004-01-23 | Completed | ||
| Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older[NCT01039363] | Phase 2 | 27 participants (Anticipated) | Interventional | Not yet recruiting | |||
| Phase II Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia[NCT00326170] | Phase 2 | 34 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Selected Hematologic Malignancies[NCT00079378] | Phase 1 | 84 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.[NCT03467178] | Phase 2 | 119 participants (Anticipated) | Interventional | 2018-07-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical activity of combination defined as: Complete Response (CR), bone marrow with 5% or fewer blasts and peripheral blood count with an absolute neutrophil count of 10^9/L or more and platelet count of 100x10^9 or more; Complete response without platelets (CRp), a complete response except for a platelet count less than 100x10^9 and transfusion independent; and Bone Marrow (BM) Response, bone marrow blast of 5% or less but without meeting the peripheral blood count criteria for (CR) or (CRp). (NCT00326170)
Timeframe: Up to 12 cycles of treatment (28 day cycles)
| Intervention | Participants (Number) | ||
|---|---|---|---|
| CR | CRp | BM | |
| VPA + 5-aza + ATRA | 12 | 3 | 7 |
4 reviews available for valproic acid and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Efficacy and Safety of Valproic Acid in Myelodysplastic Syndrome and Acute Myeloid Leukemia; a Narrative Review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Myelodysplas | 2023 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progre | 2015 |
Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Enzyme Inhibitors; Humans; Leukemia, Myeloid, | 2008 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; | 2011 |
16 trials available for valproic acid and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Idarubicin; Lenalidomide; Leuke | 2022 |
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Decitabine; Disease-Free Su | 2020 |
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Decitabine; Disease-Free Su | 2020 |
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Decitabine; Disease-Free Su | 2020 |
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Decitabine; Disease-Free Su | 2020 |
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Critical Care; Cytarabine; Disease-Free Survival; Dr | 2014 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute mye
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Proto | 2015 |
Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
Topics: Adult; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Repair; Gene Regulatory Networks; Histone Deacet | 2016 |
Elevated FOSB-expression; a potential marker of valproate sensitivity in AML.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Drug Resista | 2009 |
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; | 2011 |
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Azacitidin | 2010 |
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites | 2011 |
Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cytarab | 2012 |
Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarab | 2012 |
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Blotting, Western; Dose-Response Relationship, Drug; | 2005 |
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; Decit | 2006 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
48 other studies available for valproic acid and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing.
Topics: Anticonvulsants; Antioxidants; Bezafibrate; Cell Line, Tumor; Contraceptive Agents, Hormonal; Humans | 2022 |
Acetylation stabilizes the signaling protein WISP2 by preventing its degradation to suppress the progression of acute myeloid leukemia.
Topics: Acetylation; Apoptosis; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Histone Deacetylase | 2023 |
Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
Topics: Animals; Cell Line, Tumor; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Mice; N | 2023 |
Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.
Topics: Aged; Aged, 80 and over; Amino Acids; Cytarabine; Drug Therapy; Female; Humans; Hydroxyurea; Leukemi | 2019 |
p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy.
Topics: Adult; Aged; Aged, 80 and over; Blast Crisis; Cell Differentiation; Cell Line, Tumor; Epigenesis, Ge | 2021 |
p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy.
Topics: Adult; Aged; Aged, 80 and over; Blast Crisis; Cell Differentiation; Cell Line, Tumor; Epigenesis, Ge | 2021 |
p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy.
Topics: Adult; Aged; Aged, 80 and over; Blast Crisis; Cell Differentiation; Cell Line, Tumor; Epigenesis, Ge | 2021 |
p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy.
Topics: Adult; Aged; Aged, 80 and over; Blast Crisis; Cell Differentiation; Cell Line, Tumor; Epigenesis, Ge | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Computational Biology; Fema | 2017 |
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Computational Biology; Fema | 2017 |
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Computational Biology; Fema | 2017 |
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Computational Biology; Fema | 2017 |
Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
Topics: Biomarkers, Tumor; Decitabine; Demethylation; DNA Methylation; DNA Modification Methylases; Down-Reg | 2019 |
Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Female; Humans; Interfero | 2019 |
[Effect of valproic acid against angiogenesis of Kasumi-1 xenograft tumor in nude mice].
Topics: Angiopoietins; Animals; Antigens, CD34; Cell Line, Tumor; Female; Humans; Leukemia, Myeloid, Acute; | 2013 |
Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; | 2013 |
Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi‑1 leukemia cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factor 2; Gene Expressio | 2014 |
Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
Topics: Aged; Anticonvulsants; Cell Death; Cell Differentiation; Cell Line, Tumor; Dasatinib; Drug Synergism | 2014 |
Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; D | 2015 |
Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anticonvulsants; Antineoplastic Agents; Apoptos | 2016 |
Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 Cells.
Topics: Acetylation; Amino Acid Motifs; Amino Acid Sequence; Cluster Analysis; Computational Biology; HL-60 | 2016 |
Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Chloroquine; Drug Synergism; Female; Histone Deacetylase Inhibitors; Hu | 2016 |
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Bone Marrow Cells; | 2016 |
Establishment and Characterization of Long-Term Cultures Derived from Primary Acute Myeloid Leukemia Cells for HDAC Inhibitor Research.
Topics: Antigens, CD34; Apoptosis; Biomarkers, Tumor; Cell Culture Techniques; Cell Proliferation; Cell Sepa | 2017 |
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
Topics: Adult; Cation Transport Proteins; Chromatin Assembly and Disassembly; DNA Methylation; DNA, Neoplasm | 2008 |
A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts.
Topics: Azacitidine; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Female; Gran | 2008 |
A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
Topics: Aged; Aged, 80 and over; Blood Cell Count; Drug Therapy, Combination; Female; Humans; Leukemia, Myel | 2009 |
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
Topics: Adult; Aged; Blast Crisis; Cytotoxicity, Immunologic; Female; GPI-Linked Proteins; Histone Deacetyla | 2009 |
Valproic acid exerts differential effects on CXCR4 expression in leukemic cells.
Topics: Antigens, CD34; Cell Differentiation; Chemotaxis; Gene Expression Regulation, Leukemic; HL-60 Cells; | 2010 |
Diagnostic exercise: sudden death in a mouse with experimentally induced acute myeloid leukemia.
Topics: Acute Disease; Animals; Antineoplastic Agents; Death, Sudden; Disease Models, Animal; Female; Leukem | 2009 |
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.
Topics: Apoptosis; Caspase 3; Caspase 9; Cytarabine; DNA Damage; Drug Synergism; Humans; Leukemia, Myeloid, | 2010 |
The effect of a histone deacetylase inhibitor - valproic acid - on nucleoli in human leukaemic myeloblasts.
Topics: Cell Nucleolus; Cell Shape; Cells, Cultured; Granulocyte Precursor Cells; Histone Deacetylase Inhibi | 2010 |
Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Ce | 2011 |
An inexpensive way to treat elderly patients with high-risk MDS or AML.
Topics: Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites, Antineoplastic; Cytarab | 2011 |
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
Topics: Acetylation; Animals; Antigens, CD34; Apoptosis; Cell Line, Tumor; Flow Cytometry; Gene Expression R | 2012 |
Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.
Topics: Apoptosis; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Chromosomes, Human, Pair 21; Chromoso | 2012 |
Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Line, Tu | 2012 |
Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute | 2012 |
Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.
Topics: Animals; Caenorhabditis elegans; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacet | 2012 |
Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD1 | 2013 |
Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Topics: Acetylation; Apoptosis; Cell Differentiation; Core Binding Factor Alpha 2 Subunit; Gene Expression R | 2013 |
The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; C | 2005 |
Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
Topics: Butyrates; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; C | 2005 |
Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Humans; Leukem | 2005 |
Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report.
Topics: Aminophylline; Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins; Drug Therapy, C | 2006 |
Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia.
Topics: Aged, 80 and over; Aminophylline; Blood Platelets; Drug Therapy, Combination; Female; Humans; Leukem | 2006 |
Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carrier Pro | 2006 |
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Enzyme Inhibitors; Humans; In Situ H | 2006 |
The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antigen | 2007 |
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Topics: Acetylation; Amino Acid Chloromethyl Ketones; Apoptosis; Caspase 3; Caspase 9; Cell Differentiation; | 2007 |
Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.
Topics: Adult; Aged; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gene E | 2007 |
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Topics: Cell Line; Cell Survival; Cytotoxicity, Immunologic; Enzyme Inhibitors; GPI-Linked Proteins; Histoco | 2008 |
Induction of neutrophilic differentiation of human promyelocytic leukemic cells by branched-chain carboxylic acid anticonvulsant drugs.
Topics: Anticonvulsants; Antineoplastic Agents; Cell Differentiation; Cell Division; Cells, Cultured; Cycloh | 1984 |